ProShares UltraShort Bloomberg Natrl Gas

Direxion Daily Small Cap Bear 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Technology Bull 3X ETF

Direxion Daily Semicondct Bull 3X ETF

ProShares Ultra Silver

Direxion Daily S&P Biotech Bear 3X ETF

Bank Of Montreal

ProShares Bitcoin Strategy ETF

Deutsche X-trackers Harvest CSI300 CHN A

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Small Cap Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

VS TR 2x Long VIX Futures ETF

Real Estate Select Sector SPDR

Direxion Daily Semicondct Bear 3X ETF

United States Natural Gas

Direxion Technology Bear 3X Shares

ProShares UltraShort Silver

QuantumScape Corporation Class A Common Stock

AgEagle Aerial Systems Inc. Common Stock

Dick's Sporting Goods Inc Common Stock

Kennametal Inc. Common Stock

ICL Group Ltd. Ordinary Shares

Endeavour Silver Corporation Ordinary Shares (Canada)

Cloudflare Inc. Class A Common Stock

Affiliated Managers Group Inc. Common Stock

Alamos Gold Inc. Class A Common Shares

The AZEK Company Inc. Class A Common Stock

Winnebago Industries Inc. Common Stock

Oklo Inc.

Primerica Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Boston Properties Inc. Common Stock

Civitas Resources Inc. Common Stock

Gates Industrial Corporation plc Ordinary Shares

XPeng Inc. American depositary shares each representing two Class A ordinary shares

EQT Corporation Common Stock

Granite Point Mortgage Trust Inc. Common Stock

Click here to get full coverage on Mainz Biomed Secures Major Government Funding for Revolutionary Blood-Based Pancreatic Cancer Test - Stock Titan

Mainz Biomed Secures Major Government Funding for Revolutionary Blood-Based Pancreatic Cancer Test  Stock Titan

Mainz Biomed Secures Major Government Funding for Revolutionary Blood-Based Pancreatic Cancer Test - Stock Titan

Click here to get full coverage on Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewswire

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test  GlobeNewswire

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewswire

Click here to get full coverage on Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer - GuruFocus

Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer  GuruFocus

Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer - GuruFocus

Click here to get full coverage on Where are the Opportunities in (MYNZ) - news.stocktradersdaily.com

Where are the Opportunities in (MYNZ)  news.stocktradersdaily.com

Where are the Opportunities in (MYNZ) - news.stocktradersdaily.com

Click here to get full coverage on Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq

Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation  Nasdaq

Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq

Click here to get full coverage on Mainz Biomed secures public funding to advance pancreatic cancer screening test - TipRanks

Mainz Biomed secures public funding to advance pancreatic cancer screening test  TipRanks

Mainz Biomed secures public funding to advance pancreatic cancer screening test - TipRanks

Click here to get full coverage on Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - Stock Titan

Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position  Stock Titan

Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - Stock Titan

Click here to get full coverage on Revolutionary Blood Test Detects Pancreatic Cancer with 95% Accuracy, Mainz Biomed Study Reveals - Stock Titan

Revolutionary Blood Test Detects Pancreatic Cancer with 95% Accuracy, Mainz Biomed Study Reveals  Stock Titan

Revolutionary Blood Test Detects Pancreatic Cancer with 95% Accuracy, Mainz Biomed Study Reveals - Stock Titan

Click here to get full coverage on Mainz Biomed Enters into Technology Partnership with EDX Medical Group - GlobeNewswire

Mainz Biomed Enters into Technology Partnership with EDX Medical Group  GlobeNewswire

Mainz Biomed Enters into Technology Partnership with EDX Medical Group - GlobeNewswire

Click here to get full coverage on Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan

Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering  Stock Titan

Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan

Click here to get full coverage on Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants  GlobeNewswire

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire

Click here to get full coverage on Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan

Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial  Stock Titan

Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan

Click here to get full coverage on Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update  GlobeNewswire

Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Revolutionary mRNA Blood Test Detects Pancreatic Cancer with Near-Perfect Accuracy - Stock Titan

Revolutionary mRNA Blood Test Detects Pancreatic Cancer with Near-Perfect Accuracy  Stock Titan

Revolutionary mRNA Blood Test Detects Pancreatic Cancer with Near-Perfect Accuracy - Stock Titan

Click here to get full coverage on Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval  GlobeNewswire

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire

Click here to get full coverage on Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues - Stock Titan

Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues  Stock Titan

Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues - Stock Titan

Click here to get full coverage on Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study  GlobeNewswire

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire

Click here to get full coverage on Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.  Nasdaq

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq

Click here to get full coverage on Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - GlobeNewswire

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets  GlobeNewswire

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - GlobeNewswire

Click here to get full coverage on Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced  GlobeNewswire

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire

Click here to get full coverage on Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire

Mainz Biomed Expands into Switzerland with labor team w  GlobeNewswire

Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire

Click here to get full coverage on Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan

Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial  Stock Titan

Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan

Click here to get full coverage on Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire

Mainz Biomed and Liquid Biosciences Make Groundbreaking  GlobeNewswire

Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire

Click here to get full coverage on Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - Stock Titan

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025  Stock Titan

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - Stock Titan

Click here to get full coverage on Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire

Mainz Biomed Forms Agreement with Quest Diagnostics to  GlobeNewswire

Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire

Click here to get full coverage on Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus

Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert  GuruFocus

Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus

Click here to get full coverage on Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire

Mainz Biomed Initiates U.S. Clinical Study to Evaluate  GlobeNewswire

Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire

Click here to get full coverage on Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update  GlobeNewswire

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study  GlobeNewswire

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire

Click here to get full coverage on Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention  GlobeNewswire

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire

Click here to get full coverage on Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025  GlobeNewswire

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - GlobeNewswire

Click here to get full coverage on MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus

MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i  GuruFocus

MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus

Click here to get full coverage on Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening  Nasdaq

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq

Click here to get full coverage on Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough - Stock Titan

Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough  Stock Titan

Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough - Stock Titan

Click here to get full coverage on Mainz Biomed stock hits 52-week low at $3.65 amid sharp annual decline - Investing.com

Mainz Biomed stock hits 52-week low at $3.65 amid sharp annual decline  Investing.com

Mainz Biomed stock hits 52-week low at $3.65 amid sharp annual decline - Investing.com

Click here to get full coverage on Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com

Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges  Investing.com

Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com

Click here to get full coverage on Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - Stock Titan

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador  Stock Titan

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador - Stock Titan

Click here to get full coverage on Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks

Mainz Biomed Reports 2024 Financial Success and Strategic Advances  TipRanks

Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks

Click here to get full coverage on Mainz Biomed Partners with Liquid Biosciences to Leverage - GlobeNewswire

Mainz Biomed Partners with Liquid Biosciences to Leverage  GlobeNewswire

Mainz Biomed Partners with Liquid Biosciences to Leverage - GlobeNewswire

Click here to get full coverage on Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks

Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting  TipRanks

Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting - TipRanks

Click here to get full coverage on Mainz Biomed to hold annual meeting on June 2 - Investing.com

Mainz Biomed to hold annual meeting on June 2  Investing.com

Mainz Biomed to hold annual meeting on June 2 - Investing.com

Click here to get full coverage on Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com

Mainz Biomed stock hits 52-week low at $0.18 amid market challenges  Investing.com

Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com

Click here to get full coverage on Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq

Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test  Nasdaq

Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq

Click here to get full coverage on Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge - GlobeNewswire

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge  GlobeNewswire

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge - GlobeNewswire

Click here to get full coverage on Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones - Nasdaq

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones  Nasdaq

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones - Nasdaq

Click here to get full coverage on LLY: 3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025 - StockNews

LLY: 3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025  StockNews

LLY: 3 Healthcare Stocks to Buy Now for a Healthy Portfolio in 2025 - StockNews

Click here to get full coverage on Mainz Biomed Announces Submission for FDA Breakthrough - GlobeNewswire

Mainz Biomed Announces Submission for FDA Breakthrough  GlobeNewswire

Mainz Biomed Announces Submission for FDA Breakthrough - GlobeNewswire

Click here to get full coverage on Mainz Biomed plans FDA trial for cancer test in 2025 - Investing.com

Mainz Biomed plans FDA trial for cancer test in 2025  Investing.com

Mainz Biomed plans FDA trial for cancer test in 2025 - Investing.com

Click here to get full coverage on Mainz Biomed partners with Quest for colorectal cancer test - Investing.com

Mainz Biomed partners with Quest for colorectal cancer test  Investing.com

Mainz Biomed partners with Quest for colorectal cancer test - Investing.com

Click here to get full coverage on What Makes Mainz Biomed NV (MYNZ) a New Buy Stock - Yahoo Finance

What Makes Mainz Biomed NV (MYNZ) a New Buy Stock  Yahoo Finance

What Makes Mainz Biomed NV (MYNZ) a New Buy Stock - Yahoo Finance

Click here to get full coverage on Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer

Mainz Biomed announces 1-for-40 reverse stock split  Medical Buyer

Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer

Click here to get full coverage on Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - The Manila Times

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants  The Manila Times

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - The Manila Times

Click here to get full coverage on Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate - Nasdaq

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate  Nasdaq

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate - Nasdaq

Click here to get full coverage on Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com India

Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com  Investing.com India

Mainz Biomed BV (MYNZ)

Price Chart

Key Statistics

Technicals

About MYNZ

Latest News

Mainz Biomed Secures Major Government Funding for Revolutionary Blood-Based Pancreatic Cancer Test - Stock Titan

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test - GlobeNewswire

Mainz Biomed (MYNZ) Secures State Funding for Pancreatic Cancer - GuruFocus

Advanced Charts

Top Gainers

Top Losers